@article {Li:2014:1021-335X:1961,
title = "Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer",
journal = "Oncology Reports",
parent_itemid = "infobike://sp/or",
publishercode ="sp",
year = "2014",
volume = "31",
number = "4",
publication date ="2014-01-01T00:00:00",
pages = "1961-1967",
itemtype = "ARTICLE",
issn = "1021-335X",
eissn = "1791-2431",
url = "https://www.ingentaconnect.com/content/sp/or/2014/00000031/00000004/art00062",
doi = "doi:10.3892/or.2014.3029",
author = "Li and Zhang and Wu and Jia and Shi and Li and Peng and Zhang and Song and Wang",
abstract = "The aim of the present study was to determine whether serum miR-499 may be used as a biomarker for early detection of non-small cell lung cancer (NSCLC). The present study was designed as an initial screening phase and a subsequent validation phase. In the screening phase, we analyzed
serum levels of miR-499 in a subset of 40patients with stageI (n=20) and stageIV (n=20) NSCLC. In the validation phase, miR-499 expression levels in serum (n=514) and tissue (n=136) from NSCLC patients were detected in a large and independent cohort of 514patients.
miR-499 in the screening phase was found to be significantly elevated in the serum of stageI NSCLC patients compared with that in stageIV NSCLC patients (P<0.001). Validation analysis showed that serum miR-499 levels were robust in differentiating NSCLC patients from control
subjects [area under the curve (AUC)=0.906; 95% confidence interval (CI)=0.879 to0.929). Serum miR-499 levels were significantly lower in stageIII andIV patients compared with those with stageI (both P<0.001) orII (both P<0.001). Low serum miR-499 levels
were associated with shorter overall survival and served as an independent prognostic biomarker in NSCLC patients [hazard ratio (HR)=1.63; 95%CI=1.33-2.0; P<0.0001). In addition, low serum levels of miR-499 indicated a poor disease-free survival in stageI-II NSCLC patients.
Serum miR-499 may prove to be a promising biomarker for early detection and prognosis prediction of NSCLC.",
}